9/27/2022  9:13:07 AM Chg. +0.18 Volume Bid9:13:35 AM Ask9:13:16 AM Market Capitalization Dividend Y. P/E Ratio
57.84CHF +0.31% 7,377
Turnover: 428,583.83
57.80Bid Size: 42 58.04Ask Size: 118 28.21 bill.CHF - -

Business description

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, the company offers the broadest portfolio of products to enhance sight and improve people’s lives. Its Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. More than 20,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care.
 

Management board & Supervisory board

CEO
David Endicott
Management board
Tim Stonesifer, Ian Bell, Laurent Attias, Rajkumar Narayanan, Sergio Duplan, Sue-Jean Lin
Supervisory board
F. Michael Ball, Arthur Cummings, D. Keith Grossman, David J. Endicott, Dieter Spälti, Ines Pöschel, Karen May, Lynn Bleil, Scott Maw, Thomas Glanzmann
 

Company data

Name: Alcon Inc.
Address: Chemin de Blandonnet 8,CH-1214 Vernier, Geneva
Phone: +41-589-112-110
Fax: -
E-mail: investor.relations@alcon.com
Internet: https://www.alcon.com
Industry: Healthcare
Sector: Medical Products
Sub sector: Advanced Medical Devices
End of financial year: 12/31
Free Float: -
IPO date: 4/9/2019

Investor relations

Name: Karen King
IR phone: -
IR Fax: -
IR e-mail: -

Company calendar

CW 47 | 11/16/2022 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Freefloat
 
89.60%
Emasan AG
 
3.70%
BlackRock, Inc.
 
3.60%
The Capital Group Companies, Inc.
 
3.10%
Others
 
0.00%